Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Proof of Concept Trial Including Asymptomatic Individuals Using Baricitinib

Next Previous
Trial Profile

Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Proof of Concept Trial Including Asymptomatic Individuals Using Baricitinib

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baricitinib (Primary)
  • Indications Alzheimer's disease; Amyotrophic lateral sclerosis; Dementia; Mild cognitive impairment
  • Focus Biomarker; Pharmacokinetics; Proof of concept
  • Acronyms NADALS

Most Recent Events

  • 04 Oct 2024 Status changed from recruiting to active, no longer recruiting.
  • 18 Mar 2024 Planned End Date changed from 1 Oct 2024 to 1 Jun 2025.
  • 18 Mar 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top